Abstract
Objectives Financial conflicts of interest (FCOI) between pharmaceutical companies (Pharma) and healthcare domains may unduly influence physician-led clinical practice and patient-centered care. However, the extent of awareness and perceptions of FCOI among Japanese cancer patients remains unclear. This study aimed to assess these factors and their impacts on physician trustworthiness among Japanese cancer patients.
Methods A cross-sectional study using self-administered surveys was conducted on a Japanese cancer patient advocacy group with 800 registered members from January to February 2019. Main outcome measures included awareness and perceptions of physician-Pharma interactions, their impact on physician trustworthiness, and attitudes towards FCOI among professions. We also performed thematic analyses on additional comments responders provided in the surveys.
Results Among the 524 invited members, 96 (18.3%) completed the questionnaire. Of these, 69 (77.5%) were cancer patients. The proportion of participants aware of such interactions ranged from 2.1% to 65.3%, depending on the interaction type. Participants were generally neutral on how the interactions would affect physician trustworthiness. A large proportion of participants agreed that these interactions were unethical, could influence physicians’ prescribing behavior leading to unnecessary prescriptions, and negatively affect physician trustworthiness. Qualitative responses (n=56) indicated that patients expected physicians to use sound ethical judgment and avoid accepting incentives. Participants were also concerned about their treatment and the undue influence of FCOI on physicians.
Conclusion Most participants were aware of at least one FCOI between Pharma and physicians and perceived them negatively. Further efforts to regulate FCOI appear necessary to protect patient-centered care.
Competing Interest Statement
Dr. Saito receives personal fees from Taiho Pharmaceutical Co., Ltd. outside the scope of the submitted work. Dr. Ozaki receives personal fees from Medical Network Systems outside the scope of the submitted work. Dr. Tanimoto receives personal fees from Medical Network Systems and Bionics Co. Ltd. outside the scope of the submitted work. The remaining authors declare no financial conflicts of interest. Anju Murayama, Yuki Senoo, Kayo Harada, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto, and Akihiko Ozaki report a number of studies on conflicts of interest in Japan.
Funding Statement
This study was funded in part by the Medical Governance Research Institute. This nonprofit enterprise receives donations from pharmaceutical companies, including Ain Pharmaciez, Inc., other organizations, and private individuals. This study also received support from the Tansa (formerly known as Waseda Chronicle), an independent nonprofit news organization dedicated to investigative journalism. Ain Pharmacies had no role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, the preparation, review, and approval of the manuscript, or the decision to submit the manuscript for publication. Tansa was engaged in the collection and management of the payment data but had no role in the design and conduct of the study, the analysis and interpretation of the data, the preparation, review and approval of the manuscript, or the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Medical Governance Research Institute granted ethics approval of this study (MG2018-07-0928), adhering to the Ministry of Health Labour and Welfare and The Ministry of Education guidelines, Culture, Sports, Science, and Technology in Japan.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Equally contributed to the work.
Conflicts of interest Dr. Saito receives personal fees from Taiho Pharmaceutical Co., Ltd. outside the scope of the submitted work. Dr. Ozaki receives personal fees from Medical Network Systems outside the scope of the submitted work. Dr. Tanimoto receives personal fees from Medical Network Systems and Bionics Co. Ltd. outside the scope of the submitted work. The remaining authors declare no conflicts of interest.
Funding This study was funded in part by the Medical Governance Research Institute. This non-profit enterprise receives donations from pharmaceutical companies, including Ain Pharmaciez, Inc., other organizations, and private individuals. This study also received support from the Waseda Chronicle, an independent non-profit news organization dedicated to investigative journalism.
Abbreviations: FCOI: Financial conflicts of interest; United States (US); Pharma: Pharmaceutical companies
Data Availability
The data that support the findings of this study are available on request from the corresponding author, AM. The data are not publicly available due to their containing information that could compromise the privacy of research participants.
